Sir, We read with great interest the letter by Kö ser et al., 1 responding to our article on the characterization of the embB gene in the area of Barcelona.
1 raise is very interesting and deserves further comment. Codon 378 has indeed been described by several authors as a phylogenetic polymorphism not related to resistance.
3,4 However, in our opinion the role of this codon remains unclear, since some studies describe the existence of ethambutol-resistant isolates with a mutation only in this codon. 5, 6 Even one work 7 cited by Kö ser et al. 1 includes two isolates with a single Glu378Ala substitution and a decreased susceptibility to ethambutol.
The design of our microarray was based on the existing literature, taking into account all the possible embB codons that have been implicated in ethambutol resistance. We finally included the ones that were also found in our setting. The microarray system was not designed to determine the association of each mutation with the phenotypic resistance (allelic exchange experiments would be required for this purpose), but to reflect the variety of embB substitutions prevalent in our area. Moreover, the frequency of mutations in embB378 is low (,2% in our study), so we consider that the probability of misassigning a result of embB378 mutation to phenotypic resistance rather than to an epidemiological cause is negligible and does not compromise the effectiveness of the microarray.
Regarding the isolates, we included a collection of Mycobacterium tuberculosis complex (MTBC) clinical isolates (not identified to the species level). Isolate 233R has now been analysed and identified as M. tuberculosis/Mycobacterium canettii. It contains the embB378Glu variant; therefore, a homoplastic event may be present (experimental error was ruled out).
Likewise, the MIRU-VNTR genotyping was performed not for epidemiological purposes (i.e. for the identification of lineages), but to establish the real frequency of embB mutations among circulating MTBC isolates in our geographical area.
Finally, we stress that the main objective of this study was to highlight the relevance of mutations in embB codons apart from embB306, focusing on codon 406, which represents 20% of the embB mutations in our area. Our results show that this target (embB406) should be included in any genotypic method for rapid ethambutol resistance detection.
Transparency declarations
None to declare. 1 published in this journal reported the action of S-nitrosoglutathione (GSNO) (CAS number: 57564-91-7) on skin disease induced by Leishmania parasites. The major findings of this study were: (i) GSNO following topical application reduced ulcerated skin lesions of infected mice; and (ii) the number of intracellular Leishmania major amastigotes is reduced in THP-1 macrophages exposed to 300 mM GSNO. The authors assume that the nitrosation by GSNO of host cell and parasite proteins could explain the in vitro leishmanicidal activity of GSNO in THP-1 cell culture.
We suggest a complementary mechanism of GSNO action. We have recently analysed the transcriptome of THP-1 cells exposed to 50 mM GSNO for 4 h. Some of our results might be of high interest with regard to those obtained by Costa et al.:
1 analysis of the protein -protein interaction of differentially expressed genes (fold change ≤0.5 or ≥2, P, 0.001) in response to GSNO shows the involvement of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway called 'cytokine-cytokine receptor interaction'. This pathway links the human genes CCL4, CCL3, Figure 1 . Protein-protein interactions of 128 modified genes in THP-1 cells exposed to 50 mM GSNO for 4 h, as retrieved from the String database. Total RNA was extracted and analysed by microarray. One hundred and three of 128 genes whose expression was significantly altered and recognized by the String database were linked at the confidence, evidence or action level. Proteins involved in the cytokine -cytokine receptor interaction KEGG pathway are shown in red. Microarray results were confirmed by real-time PCR for CCL4 and VEGFA genes (up-regulated 21.9-and 3.4-fold, respectively, P, 0.001, as determined by Student's t-test). The detailed protocol and the raw data of the microarrays are available on the GEO NCBI database using the accession number GSE51186. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
CCL20, INHBA, VEGFA and IL23A, which are overexpressed 3-to 15-fold compared with control ( Figure 1 ). Chemokines, which coordinate the recruitment of leucocytes involved in homeostasis and in innate and adaptive immune responses, play a crucial role in the regulation of immunity against Leishmania. 2 In addition, CCL3 and CCL20 have been shown to display antiparasitic activity against the promastigote form of the Leishmania mexicana parasite by acting directly on plasma membranes on Leishmania parasites, causing their lysis.
3 Evidence of an increase in phagocytosis and NO-mediated destruction of Leishmania by chemokines (including CCL3 and CCL4) was reported a decade ago. 4 Moreover, we show here that IL-23A levels are induced by GSNO. Murray et al. 5 showed that IL-23 displayed an antileishmanial effect, especially during late-stage parasitic infection. Thus, GSNO may be implicated in a cellular signalling pathway leading to macrophage activation and exhibiting immunostimulatory effects.
Our results indicate that GSNO not only exhibits microcidal activity but also acts as a macrophage activator. This activation was possible with the involvement of at least three chemokines (CCL4, CCL3 and CCL20) and one cytokine (IL23A). All of them are known to have antiparasitic activity, and thus could be effective against Leishmania infection. In conclusion, our results may be relevant to investigators working on GSNO antiparasitic activity in vitro and in vivo.
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Sir, Thank you to Ronzani et al. 1 for calling attention to our paper. The results reported by Ronzani et al. 1 are certainly interesting as they indicate that expression of chemokines and cytokines in a human monocyte cell line (THP-1) can be up-regulated by S-nitrosoglutathione (GSNO). Although most studies have reported down-regulation of the synthesis of most proteins, up-regulation also occurs and the net result of GSNO action appears to be much dependent on the levels of nitrosoglutathione reductase expressed by each cell type. 3, 4 In addition, NO and GSNO also act post-transcriptionally and directly inhibit the phosphorylation of transcription factors such as STAT-3. 5 Regarding the activities of chemokines and cytokines on Leishmania infection, these molecules are secreted by several host cells of the innate or acquired immunity systems. They are secreted to the extracellular milieu and act by recruiting and/or activating the respective cell targets, e.g. neutrophils, lymphocytes and macrophages (after interaction with target-cell membrane receptors). 6 Thus, chemokines and cytokines are recognized as important regulators of the immune and inflammatory responses and because of this many participate in the control of Leishmania parasitism in the vertebrate host. Regarding a possible direct cytotoxic activity of chemokines/ cytokines against Leishmania, it should be recalled that the study by Sö birk et al.
8 described this cytotoxicity to occur against free promastigotes of Leishmania, at micromolar concentrations of these mediators in contrast to the nanomolar levels normally found in the inflammatory microenvironment.
However, in the cultures of Leishmania-infected THP-1 cells described in our paper, 2 the parasites were amastigotes lying inside parasitophorous vacuoles in the cytoplasm. Therefore,
